Abstract
There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus-related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.
MeSH terms
-
Evaluation Studies as Topic
-
Fluorodeoxyglucose F18
-
Head and Neck Neoplasms / diagnostic imaging*
-
Head and Neck Neoplasms / radiotherapy
-
Humans
-
Magnetic Resonance Imaging / methods*
-
Magnetic Resonance Imaging / standards
-
Multimodal Imaging / methods
-
Multimodal Imaging / standards
-
Positron Emission Tomography Computed Tomography / methods*
-
Positron Emission Tomography Computed Tomography / standards
-
Radiopharmaceuticals
-
Randomized Controlled Trials as Topic
-
Squamous Cell Carcinoma of Head and Neck / diagnostic imaging*
-
Squamous Cell Carcinoma of Head and Neck / radiotherapy
Substances
-
Radiopharmaceuticals
-
Fluorodeoxyglucose F18